AARON THRIFT to Proton Pump Inhibitors
This is a "connection" page, showing publications AARON THRIFT has written about Proton Pump Inhibitors.
Connection Strength
1.685
-
Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
Score: 0.514
-
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
Score: 0.465
-
Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies. Dig Dis Sci. 2023 09; 68(9):3732-3744.
Score: 0.165
-
Decreasing Overall and Inappropriate Proton Pump Inhibitor Use:?Perspective From a Large Safety-Net Healthcare System. Clin Gastroenterol Hepatol. 2020 04; 18(4):763-766.e2.
Score: 0.129
-
Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018 07; 48(1):55-64.
Score: 0.115
-
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Gastroenterol. 2016 07; 32(4):319-24.
Score: 0.101
-
Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2225-32.
Score: 0.093
-
Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
Score: 0.081
-
Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
Score: 0.023